Abstract

Developmental funds are a major source of flexible funding for the Sidney Kimmel Comprehensive Cancer Center (SKCCC). These funds have allowed the Center to strengthen its scientific programs and provide scientists the opportunity to explore innovative ideas and new collaborations. These funds are critical to maintaining and extending the research vitality of the scientific programs in the SKCCC. Use of these funds is tightly linked to the formal planning and evaluation activifies of the Center. A review of the priority of programmatic needs for new faculty recruitment by the Director, Associate Directors and Program Leaders has resulted in this esfimated allocation of development funds per year during this next CCSG cycle to new faculty investigators $400,000 (66.7%), pilot projects $100,000 (16.6%), and shared resource development $100,000 (16.7%). Funds in the amount of $600,000 in Developmental Funds per year are requested. These funds will be instrumental in achieving the goals of SKCCC's strategic planning. Given the expansion in the SKCCC's research programs and sponsored funding (an increase of over 100% in the last five years), this increase can be justified.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-50
Application #
8559778
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
50
Fiscal Year
2013
Total Cost
$427,516
Indirect Cost
$163,616

  Institution

Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218

  Publications

Woodard, Lauren E; Dennis, Cindi L; Borchers, Julie A et al. (2018) Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality. Sci Rep 8:12706
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Gordy, James T; Luo, Kun; Francica, Brian et al. (2018) Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3?-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons. J Immunother 41:181-189
El-Diwany, Ramy; Soliman, Mary; Sugawara, Sho et al. (2018) CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans. Sci Adv 4:eaat0843
Kyker-Snowman, Kelly; Erlanger Avigdor, Bracha; Nasim, Mansoor et al. (2018) A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing. Breast Cancer Res Treat 170:425-430
Christenson, Eric S; Antonarakis, Emmanuel S (2018) PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs 23:123-133
Ambinder, Richard F (2018) A viral protein kinase drug target for tumors? J Clin Invest 128:2197-2198
Lee, Alice J; Montgomery, Madeline C; Patel, Rupa R et al. (2018) Improving Insurance and Health Care Systems to Ensure Better Access to Sexually Transmitted Disease Testing and Prevention. Sex Transm Dis 45:283-286
Bharathy, Narendra; Berlow, Noah E; Wang, Eric et al. (2018) The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma. Sci Signal 11:
McGrath-Morrow, Sharon A; Ndeh, Roland; Helmin, Kathryn A et al. (2018) DNA methylation regulates the neonatal CD4+ T-cell response to pneumonia in mice. J Biol Chem 293:11772-11783

Showing the most recent 10 out of 2393 publications